- Expanding the Mutational Spectrum in Juvenile Myelomonocytic LeukemiaFebruary 19, 2016 | Elizabeth Raetz, MD
Dr. Raetz evaluates a study that sheds new light on the pathogenesis and genetic complexity of JMML and offers opportunities for new therapeutic developments.
- Novel Targets in Primary Central Nervous System LymphomaFebruary 19, 2016 | Ann S. LaCasce, MD, MSc
Dr. LaCasce explores therapies used to target lymphoma involving the central nervous system (CNS) and primary testicular lymphoma, unique subtypes of DLBCL.
- Chimeric Antigen Receptor T Cells for the Treatment of Multiple MyelomaFebruary 17, 2016
Drs. Raje and O'Donnell shed light on the use of chimeric antigen receptor (CAR) T cells for the treatment of multiple myeloma.
- Short-Term Treatment Strategies for Recurrent Venous ThromboembolismFebruary 17, 2016 | David Garcia, MD
Dr. Garcia takes a look at a study that observes treatment of cancer patients after a breakthrough VTE to help clinicians and investigators define management of patients experiencing VTE recurrence despite anticoagulation.
- Antithymocyte Globulin Proves a Promising Ally Against GVHDFebruary 16, 2016 | Paul Moss, PhD
Dr. Moss looks at the role of antithymocyte globulin (ATG) in treating graft-versus-host disease (GVHD).
- Mutated Calreticulin Stimulates the Thrombopoietin Receptor to Drive the Development of MPNFebruary 12, 2016
Drs. George and Lynch discuss research of the pathophysiology for CALR-mutated MPN and the possibility for the emergence of new therapeutic opportunities.
- One Step Closer to Functionally Characterizing the Human Genome: Genomic Screens Identify Essential Genes and Liabilities in Cancer CellsFebruary 12, 2016
Drs. Abdel-Wahab and Taylor look at several studies that have provided a set of techniques, tools, and knockout cells, which can help provide insight into new functions of our genome and new therapies to target cancer.
- What Lies Beneath? Prevalence of Heritable Mutations in Pediatric CancerFebruary 12, 2016 | Sioban Keel, MD
Dr. Keel reviews a study of the genetics of childhood cancer predisposition and lists questions that remain in determining how to most effectively incorporate germline sequencing into clinical care.
- The TWiTCH TrialFebruary 11, 2016 | Michael DeBaun, MD, MPH
Dr. DeBaun discusses the TWiTCH trial, which compares hydroxyurea with standard transfusions used to treat children with sickle cell disease and high transcranial Doppler (TCD) flow velocities.